PHAT vs. AMPH, ARDX, EVO, ETNB, OCUL, GPCR, IOVA, CALT, AUPH, and GYRE
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Phathom Pharmaceuticals vs.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Phathom Pharmaceuticals' return on equity.
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Amphastar Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals currently has a consensus price target of $43.50, suggesting a potential upside of 52.85%. Phathom Pharmaceuticals has a consensus price target of $22.17, suggesting a potential upside of 238.42%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals received 298 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. However, 72.31% of users gave Phathom Pharmaceuticals an outperform vote while only 65.99% of users gave Amphastar Pharmaceuticals an outperform vote.
In the previous week, Amphastar Pharmaceuticals had 7 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 9 mentions for Amphastar Pharmaceuticals and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.77 beat Amphastar Pharmaceuticals' score of 0.52 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Summary
Amphastar Pharmaceuticals beats Phathom Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHAT) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy PHAT Stock Free PHAT Stock Alerts